Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections-Pipeline Review, H1 2015

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections-Pipeline Review, H1 2015', provides an overview of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections Overview 7

Therapeutics Development 8

Pipeline Products for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections-Overview 8

Pipeline Products for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections-Comparative Analysis 9

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections-Therapeutics under Development by Companies 10

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections-Therapeutics under Investigation by Universities/Institutes 11

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections-Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections-Products under Development by Companies 14

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections-Products under Investigation by Universities/Institutes 15

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections-Companies Involved in Therapeutics Development 16

Arsanis Biosciences GmbH 16

ContraFect Corporation 17

ImmuVen, Inc. 18

Lytix Biopharma AS 19

Nabriva Therapeutics AG 20

PharmaIN Corporation 21

Sealife PHARMA GMBH 22

Sumitomo Dainippon Pharma Co., Ltd. 23

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections-Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29

Assessment by Molecule Type 31

Drug Profiles 33

ASN-100-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

CF-301-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

IMV-0123-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

lefamulin-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

LTX-109-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

PGC Anti-MRSA-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

SLP-0904-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

SLP-0905-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

SM-295291-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

SM-369926-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

Small Molecules for Bacterial Infections-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Synthetic Peptide for Oncology and Infectious Disease-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

targocil-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections-Recent Pipeline Updates 48

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections-Dormant Projects 51

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections-Discontinued Products 52

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections-Product Development Milestones 53

Featured News & Press Releases 53

Dec 02, 2014: ContraFect Submits Complete Response to IND Clinical Hold for CF-301 53

May 01, 2012: ImmuVen Receives $1.68m Phase II SBIR Grant From NIH For MRSA Therapeutics 53

Appendix 54

Methodology 54

Coverage 54

Secondary Research 54

Primary Research 54

Expert Panel Validation 54

Contact Us 54

Disclaimer 55

List of Tables

Number of Products under Development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections, H1 2015 8

Number of Products under Development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Number of Products under Investigation by Universities/Institutes, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Development, H1 2015 13

Products under Development by Companies, H1 2015 14

Products under Investigation by Universities/Institutes, H1 2015 15

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections-Pipeline by Arsanis Biosciences GmbH, H1 2015 16

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections-Pipeline by ContraFect Corporation, H1 2015 17

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections-Pipeline by ImmuVen, Inc., H1 2015 18

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections-Pipeline by Lytix Biopharma AS, H1 2015 19

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections-Pipeline by Nabriva Therapeutics AG, H1 2015 20

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections-Pipeline by PharmaIN Corporation, H1 2015 21

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections-Pipeline by Sealife PHARMA GMBH, H1 2015 22

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 23

Assessment by Monotherapy Products, H1 2015 24

Number of Products by Stage and Target, H1 2015 26

Number of Products by Stage and Mechanism of Action, H1 2015 28

Number of Products by Stage and Route of Administration, H1 2015 30

Number of Products by Stage and Molecule Type, H1 2015 32

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections Therapeutics-Recent Pipeline Updates, H1 2015 48

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections-Dormant Projects, H1 2015 51

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections-Discontinued Products, H1 2015 52

List of Figures

Number of Products under Development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections, H1 2015 8

Number of Products under Development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Number of Products under Investigation by Universities/Institutes, H1 2015 11

Comparative Analysis by Early Stage Products, H1 2015 13

Assessment by Monotherapy Products, H1 2015 24

Number of Products by Top 10 Targets, H1 2015 25

Number of Products by Stage and Top 10 Targets, H1 2015 26

Number of Products by Top 10 Mechanism of Actions, H1 2015 27

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 28

Number of Products by Top 10 Routes of Administration, H1 2015 29

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 30

Number of Products by Top 10 Molecule Types, H1 2015 31

Number of Products by Stage and Top 10 Molecule Types, H1 2015 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Arsanis Biosciences GmbH

ContraFect Corporation

ImmuVen, Inc.

Lytix Biopharma AS

Nabriva Therapeutics AG

PharmaIN Corporation

Sealife PHARMA GMBH

Sumitomo Dainippon Pharma Co., Ltd.

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections Therapeutic Products under Development, Key Players in Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections Therapeutics, Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections Pipeline Overview, Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections Pipeline, Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com